0001209191-19-046150.txt : 20190815
0001209191-19-046150.hdr.sgml : 20190815
20190815163347
ACCESSION NUMBER: 0001209191-19-046150
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190815
FILED AS OF DATE: 20190815
DATE AS OF CHANGE: 20190815
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mahatme Sandesh
CENTRAL INDEX KEY: 0001511034
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 191030674
MAIL ADDRESS:
STREET 1: C/O CELGENE CORPORATION
STREET 2: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930797222
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-274-4000
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-08-15
0
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001511034
Mahatme Sandesh
215 FIRST STREET, SUITE 415
CAMBRIDGE
MA
02142
0
1
0
0
EVP, CFO & CBO
Common Stock
2019-08-15
4
M
0
2863
34.92
A
23288
D
Common Stock
2019-08-15
4
M
0
3021
29.03
A
26309
D
Common Stock
2019-08-15
4
M
0
2625
13.90
A
28934
D
Common Stock
2019-08-15
4
M
0
985
13.71
A
29919
D
Common Stock
2019-08-15
4
M
0
260
13.71
A
30179
D
Common Stock
12012
I
By trust
Stock option (right to buy)
34.92
2019-08-15
4
M
0
2863
0.00
D
2014-06-04
2023-06-04
Common Stock
2863
0
D
Stock option (right to buy)
29.03
2019-08-15
4
M
0
3021
0.00
D
2015-02-28
2024-02-28
Common Stock
3021
0
D
Stock option (right to buy)
13.90
2019-08-15
4
M
0
2625
0.00
D
2016-02-27
2025-02-27
Common Stock
2625
0
D
Stock option (right to buy)
13.71
2019-08-15
4
M
0
985
0.00
D
2017-02-28
2026-02-28
Common Stock
985
2385
D
Stock option (right to buy)
13.71
2019-08-15
4
M
0
260
0.00
D
2017-02-28
2026-02-28
Common Stock
260
218
D
The reporting person executed a cash exercise of options without a subsequent sale of the underlying common stock.
/s/ David Tyronne Howton, as Attorney-in-Fact for Sandesh Mahatme
2019-08-15